 Cidara Therapeutics Inc NASDAQ: CDTX has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson Johnson NYSE: JNJ, to develop and commercialize Cidaras Cloudbreak antiviral conjugates AVCs for seasonal and pandemic influenza. Under the collaboration, Cidara will be responsible for developing and manufacturing the first influenza AVC, CD388, into the clinic and through Phase 2 development. 